Diffusing alpha-emitter radiation therapy for prostate cancer
US-11964168-B2 · Apr 23, 2024 · US
Diffusing alpha-emitter radiation therapy for prostate cancer
US12434073B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12434073-B2 |
| Application number | US-202418586598-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2024 |
| Priority date | Jun 10, 2021 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for treating a tumor, comprising identifying a tumor as a prostate cancer tumor and implanting in the tumor identified as a prostate cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source ( 21 ) with a suitable radon release rate and for a given duration, such that the source ( 21 ) provides during the given duration a cumulated activity of released radon between 7 Mega becquerel (MBq) hour and 14.7 MBq hour, per centimeter length. Each DaRT source is separated from an adjacent DaRT source in the array by less than 3.9 millimeters.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a prostate cancer tumor, comprising: identifying a tumor as a prostate cancer tumor; and implanting in the tumor identified as a prostate cancer tumor, at least one diffusing alpha-emitter radiation therapy (DaRT) source with a suitable radon release rate and for a given duration, such that the at least one DaRT source provides during the given duration a cumulated activity of released radon between 7 Mega becquerel (MBq) hour and 14.7 MBq hour, per centimeter length, wherein implanting the at least one DaRT source comprises implanting an array of DaRT sources, each DaRT source separated from an adjacent DaRT source in the array by less than 3.9 millimeters. 2. The method of claim 1 , wherein implanting the at least one DaRT source comprises implanting the array of DaRT sources in a hexagonal arrangement. 3. The method of claim 1 , wherein the at least one DaRT source has a radon release rate of between 1.5 and 3.2 microcurie per centimeter length. 4. The method of claim 3 , wherein the at least one DaRT source has a radon release rate of between 2 and 2.7 microcurie per centimeter length. 5. The method of claim 1 , wherein the method comprises selecting the given duration before implanting the at least one DaRT source in the tumor, and removing the at least one DaRT source from the tumor after the given duration from the implanting of the at least one DaRT source passed. 6. The method of claim 1 , wherein the at least one DaRT source has a radon release rate of between 2.7 and 3.2 microcurie per centimeter length.
Assignees
Inventors
Classifications
Seeds · CPC title
characterised by the type of particles applied to the patient · CPC title
Ions; Protons · CPC title
Treatment planning systems · CPC title
- A61N5/1027Primary
Interstitial radiation therapy · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12434073B2 cover?
- A method for treating a tumor, comprising identifying a tumor as a prostate cancer tumor and implanting in the tumor identified as a prostate cancer tumor, as least one diffusing alpha-emitter radiation therapy (DaRT) source ( 21 ) with a suitable radon release rate and for a given duration, such that the source ( 21 ) provides during the given duration a cumulated activity of released radon be…
- Who is the assignee on this patent?
- Alpha Tau Medical Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61N5/1027. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).